James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s Episcopal Hospital, addresses a topic of great concern in cardiology today: leakage following aortic…
James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s Episcopal Hospital, discusses groundbreaking new therapies to cure cardiovascular disease using stem cell technology.…
NEW YORK (Reuters Health) – Cardiac resynchronization therapy not only reduces the risk of a first heart failure event but also recurring events, according to an analysis of…
NEW YORK (Reuters Health) – Among patients with atrial fibrillation on amiodarone, the incidence of thyroid dysfunction is identical in those taking the brand-name formulation of the drug…
NEW YORK (Reuters Health) – A new population-based study finds the incidence of pulmonary complications associated with amiodarone to be relatively low, but still 50% higher among patients…
NEW YORK (Reuters Health) – A Danish observational study provides no evidence that use of angiotensin receptor blockers (ARBs) is associated with an increased risk of incident cancer…
NEW YORK (Reuters Health) – Atrial flutter seen in patients in the emergency department (ED) resolves more often with electrical cardioversion than with antiarrhythmic drug treatment, and long-term…
NEW YORK (Reuters Health) – For conversion of recent-onset atrial fibrillation, vernakalant acted more rapidly and was more effective than amiodarone in an international study. As reported in…
NEW YORK (Reuters Health) – In patients with chronic stable heart failure (HF) due to nonischemic dilated cardiomyopathy, a year’s treatment with n-3 polyunsaturated fatty acids (n-3 PUFAs)…
Rosuvastatin should be considered for HIV-positive people with dyslipidemia — and guidelines should be updated to reflect that, suggests a new study. Although guidelines from the Infectious Diseases…